Piper Sandler

Piper Sandler is an investment banking firm established in 1895, offering financial advisory, capital raising, and equity research services across multiple sectors including healthcare. The firm ranks as the No. 3 advisor in U.S. M&A for announced deals under $1 billion and operates the No. 2 research platform in the small and mid-cap category based on total companies under coverage.

Within healthcare, Piper Sandler provides M&A advisory, equity underwriting, and capital markets services to pharmaceutical, biotechnology, medical device, and digital health companies. Recent transactions include follow-on offerings for Arrowhead Pharmaceuticals, Monte Rosa Therapeutics, Bright Minds Biosciences, and Crinetics Pharmaceuticals, serving as active bookrunner or lead underwriter on multiple deals.

The firm recently expanded its healthcare investment banking capabilities with the addition of Dan Wolf and elevated new co-heads of healthcare investment banking. Piper Sandler maintains a global presence with transaction activity spanning multiple continents and service lines including investment banking, equities, fixed income, public finance, research, and alternative asset management.

Healthcare organizations should consider Piper Sandler when seeking experienced financial advisory for M&A transactions, equity offerings, or strategic capital markets guidance. The firm's track record in pharmaceutical and biotech transactions, combined with its middle-market M&A ranking, positions it well for companies navigating growth capital needs or exit strategies.

Engagements typically involve transaction-specific advisory services with defined timelines and outcomes. Clients can expect institutional-grade financial analysis, market positioning support, and access to capital markets relationships developed over the firm's 127-year history.

Piper Sandler serves the healthcare sector through dedicated investment banking teams focused on pharmaceuticals, biotechnology, medical devices, and digital health. The firm provides M&A advisory, equity underwriting, and capital markets services specifically tailored to healthcare companies' unique regulatory and commercialization timelines. Recent healthcare transactions demonstrate active involvement in precision medicine, biopharmaceuticals, and specialty therapeutics companies navigating public market capital raises and strategic consolidation opportunities.

The ideal client is a mid-sized pharmaceutical company, biotechnology firm, medical device manufacturer, or digital health company with $50 million to $1 billion in valuation seeking M&A advisory, follow-on equity offerings, or strategic financial guidance. Companies preparing for liquidity events, growth capital raises, or considering strategic transactions benefit most from Piper Sandler's middle-market expertise and research capabilities.